The FDA approves the first new antibiotic for nurses in almost 30 years

Food and Drug Administration Tuesday approved The first medication of a new class of antibiotics to treat urinary tract infections – the first time that has happened in almost 30 years.

The medication, a pill called Blujea of ​​the drug GSK, was approved for women and girls aged 12 and over with simple urinary tract infections – the most common type of infection in women, often caused by bacteria including E. coli.

Most urinary tract infections are easy to treat, generally emerging in a few days or weeks after a short antibiotic lesson.

But the bacteria that generally cause them are Increasingly resistant to standard antibioticsMaking the treatment more difficult, said Dr. Sovrin Shah, associate professor of urology at Mount Sinai hospital in New York.

According to the Centers for Disease Control and Prevention. A The 2019 study found Resistance to at least one medication in more than 92% of bacteria that can cause urinary tract infections. About 80% have shown resistance to at least two.

The development of new antibiotics that attack bacteria in different ways reduces the risk of drug resistance, helping to keep the processing options open, said Dr. Candace Granberg, pediatric urologist and chief surgeon at Mayo Clinic Children’s in Rochester, Minnesota.

The symptoms of the UTI include a burning sensation when urinating it, blood in the urine, a strong desire to urinate and urinate more often. Unrealized, they can lead to complications, including bladder infections and kidney damage.

“We absolutely need new antibiotics for simple urinary tract infections,” said Granberg.

Blujepa is part of a new class of antibiotics called triazaacenphylenes, which operate by targeting two key enzymes including E E. Coli need to copy and survive.

“In simple terms, this new antibiotic works its magic using a new connection method to block the capacity of a bacteria to reproduce,” said Granberg.

According to GSK, the last time the FDA cleaned a new class of antibiotics for simple urinary tract infections, it was in 1996, with the approval of fosfomycin. (Last year, the agency approved the Pivya medication for urinary tract infections, which belong to the penicillin drug class.)

In two clinical trials of phase 3 of 3,000 adults and adolescents, Blujepa has proven to be successfully treated 50% at 58% of patient infections when taken twice a day for five days, compared to 43% to 47% in a group that received the nitrofurant antibiotic.

According to a 2019 report, more than half of women will experience at least one use in their lifetime, and around 30% will undergo recurring infection.

GSK is also studying if the drug can treat gonorrhea, according to Tony Wood, scientific director of the company.

Blujepa should be available in the second half. Wood has not revealed to what extent it would cost – although, as a brand medication, its cost should be higher than other antibiotics that have been on the market for years and have generic options.

Shah, from Mount Sinai Hospital, said the cost is a significant consideration, noting that doctors would probably revolve to the credits. However, the outputization of the same antibiotics can promote resistance to drugs, so a new option is useful, he added.